BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23140274)

  • 1. Cost-effectiveness of rituximab in follicular lymphoma.
    Johnston KM; Bolbocean C; Connors J; Peacock S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):569-77. PubMed ID: 23140274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
    Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
    Blommestein HM; Issa DE; Pompen M; Ten Hoor G; Hogendoorn M; Joosten P; Zweegman S; Huijgens PC; Uyl-de Groot CA
    Eur J Haematol; 2014; 92(5):398-406. PubMed ID: 24400940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
    Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
    Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
    Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
    Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
    Prica A; Chan K; Cheung M
    Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.
    Deconinck E; Miadi-Fargier H; Pen CL; Brice P
    Pharmacoeconomics; 2010; 28(1):35-46. PubMed ID: 20014875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
    Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
    Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.
    Hayslip JW; Simpson KN
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):166-70. PubMed ID: 18650180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
    Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
    Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
    Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR
    Value Health; 2015 Mar; 18(2):189-97. PubMed ID: 25773554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance rituximab should be considered for patients with follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.
    Pink J; Lane S; Hughes DA
    Pharmacoeconomics; 2012 May; 30(5):413-29. PubMed ID: 22428718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
    Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
    Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy in follicular lymphoma.
    Michallet AS; Coiffier B; Salles G
    Curr Opin Oncol; 2011 Sep; 23(5):449-54. PubMed ID: 21734580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival.
    Prescrire Int; 2012 Mar; 21(125):63. PubMed ID: 22428183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
    Greenhalgh J; Bagust A; Boland A; Blundell M; Oyee J; Beale S; Dundar Y; Hockenhull J; Proudlove C; Chu P
    Pharmacoeconomics; 2013 May; 31(5):403-13. PubMed ID: 23576017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.